Effect of Antibiotic-Mediated Microbiome Modulation on Rotavirus Vaccine Immunogenicity: A Human, Randomized-Control Proof-of-Concept Trial

• Published in: Cell host & microbe Vol. 24; no. 2; pp. 197 - 207.e4
• Main Authors: Harris, Vanessa C., Haak, Bastiaan W., Handley, Scott A., Jiang, Baoming, Velasquez, Daniel E., Hykes, Barry L., Droit, Lindsay, Berbers, Guy A.M., Kemper, Elles Marleen, van Leeuwen, Ester M.M., Boele van Hensbroek, Michael, Wiersinga, Willem Joost
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 08.08.2018
• Subjects: Adult; Anti-Bacterial Agents - immunology; Anti-Bacterial Agents - therapeutic use; anti-IgA; Bacteroidetes; ciprofloxacin; Feces - virology; Female; Firmicutes; gastroenteritis; gastrointestinal microbiome; Gastrointestinal Microbiome - drug effects; Gastrointestinal Microbiome - immunology; Humans; Immunogenicity, Vaccine; immunoglobulin A; Immunoglobulin A - blood; Male; metronidazole; microbiota; oral vaccines; Pneumococcal Vaccines - immunology; Proteobacteria; rotavirus; rotavirus infections; rotavirus vaccines; Rotavirus Vaccines - immunology; Tetanus Toxoid - immunology; vaccines; Vaccines, Attenuated - immunology; vancomycin; Vancomycin - immunology; Vancomycin - therapeutic use; Virus Shedding; microbiota; Proteobacteria; vaccines; rotavirus infections; oral vaccines; immunoglobulin A; Bacteroidetes; Firmicutes; rotavirus vaccines; gastroenteritis; rotavirus; anti-IgA; gastrointestinal microbiome; vancomycin; metronidazole; ciprofloxacin

Rotavirus vaccines (RVV) protect against childhood gastroenteritis caused by rotavirus (RV) but have decreased effectiveness in low- and middle-income settings. This proof-of-concept, randomized-controlled, open-label trial tested if microbiome modulation can improve RVV immunogenicity. Healthy adul...